March 17, 2011

Genzyme Corporation is reporting that global supply of Thyrogen will fluctuate through July, 2011 causing temporary shortages in certain countries. Genzyme anticipates a shortage in the United States beginning in mid-April and extending through mid-June.  The company is notifying health care providers of the supply interruption so that they may schedule individual patient treatments appropriately during this time. Thyrogen continues to meet all relevant quality standards and is safe for patient use.

Additional information may be found on the Thyrogen website.

For questions, please contact Stephanie Kutler, Director of Government Affairs at The Endocrine Society at skutler@endo-society.org.